GET DAILY SIGNALSAptevo Therapeutics (APVO) Q3 2026 Earnings: Focus on Cash and Clinical Pipeline
Key Takeaways
- Aptevo Therapeutics is expected to report third-quarter 2026 results in early November 2026, with consensus calling for a net loss of roughly $3.72 per share and essentially no revenue.
- As a clinical-stage biotech, APVO's report will center on cash runway, research and development (R&D) spending, and clinical progress rather than traditional revenue growth.
- Lead candidate mipletamig continues to generate encouraging frontline acute myeloid leukemia (AML) data; investors will watch for updated RAINIER trial details.
- In the second quarter of 2026, APVO reported a narrower-than-expected loss of $5.31 per share versus the $6.02 consensus, setting a favorable comparison bar.
- A recently secured $60 million Standby Equity Purchase Agreement (SEPA) funding facility highlights both financial flexibility and potential shareholder dilution.
Why Earnings Matter for a Clinical-Stage Biotech
Aptevo Therapeutics develops multispecific immunotherapies for cancer and currently has no marketed products. Its quarterly updates therefore focus less on sales and more on how quickly cash is being used, the strength of the balance sheet, and any fresh signals from ongoing trials. The lead program, mipletamig, targets frontline acute myeloid leukemia, and recent RAINIER trial updates have shown encouraging remission rates. With a modest share count, limited cash on hand, and a track record of using equity facilities for funding, each earnings release serves as an important checkpoint on whether existing resources can support the company through its next clinical milestones.
What the Street Expects This Quarter
Wall Street consensus for the third quarter of 2026 calls for a net loss of about $3.72 per share, with estimates spanning roughly -$3.54 to -$3.89. Revenue is projected at $0, as expected for a pre-commercial biotech. For context, APVO posted a loss of $5.31 per share in the second quarter, beating the -$6.02 consensus, and a loss of $6.41 per share in the first quarter. Because EPS for companies at this stage can fluctuate with share count and non-recurring items, attention will also turn to operating expenses, cash used in operations, and the ending cash balance. Commentary on the RAINIER trial’s progress toward Phase 2 dose selection, timelines for trispecific candidates, and any updates on the $60 million SEPA facility will likely carry more weight than the headline loss number.
I also checked this using Tickeron’s AI Screener to see how APVO stacks up against peers on key financial and technical metrics.
Market Sentiment Heading Into the Report
Investor sentiment reflects a balance between positive clinical momentum and ongoing financing questions. Mipletamig’s AML data have attracted favorable analyst notes, and several recent clinical milestones have been announced. At the same time, the stock has fallen sharply from its 52-week high, and repeated use of equity facilities keeps dilution concerns prominent. Given the low share price and thinner liquidity, APVO shares tend to move sharply around earnings. Investors will be looking for signs that the cash position and trial timelines support confidence in reaching the next catalyst without a heavily dilutive raise.
What to Watch After the Print
Once the third-quarter numbers are out, the cash position and plans for funding future operations will be the primary focus. Aptevo reported $14.5 million in cash and cash equivalents as of March 31, 2026, and later secured the $60 million SEPA facility, yet the timing and size of any draws will directly affect potential dilution. On the clinical side, mipletamig and the RAINIER trial remain central; the company has indicated plans to finish Phase 1b and choose a recommended Phase 2 dose by year-end, with a possible regulatory interaction in early 2027. Progress on trispecific candidates and the Niowave collaboration in radiopharmaceuticals will also be monitored for longer-term pipeline expansion. Cost control, R&D trends, and any additional funding updates will matter equally in a competitive oncology environment.
Integrating AI Tools Into My Research Process
When preparing for earnings like APVO’s, I frequently use Tickeron’s AI Screener to quickly compare the company’s fundamentals and technical profile against industry peers. The tool lets me apply customizable filters for market cap, volatility, and performance metrics, which helps surface relevant trade ideas and context without manual screening. It has become a regular part of how I build and refine watchlists around event-driven names.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
APVO's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for APVO turned positive on November 04, 2026. Looking at past instances where APVO's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where APVO's RSI Indicator exited the oversold zone, 41 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where APVO advanced for three days, in 141 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
APVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on APVO as a result. In 94 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for APVO entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.381) is normal, around the industry mean (2.904). P/E Ratio (0.003) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. APVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of immunology and cancer research services
Industry Biotechnology
Advertisement